Dr. Dhanashri D. Khonde, Dr. Sadhana H. Khaparde, Dr. Sanjay D. Deshmukh, Dr. Baba B. Shinde


(A) Objectives: The prognosis of Gastrointestinal stromal tumors (GIST) largely depend upon the histopathological characteristics and
immunohistochemistry marker studies. This study is undertaken to study clinicopathological and immunohistochemical features of these tumors.
(B) Materials and Methods: A 6 years retrospective study (2014-2019) was conducted at a tertiary care hospital. It included all the 15 cases of
GIST diagnosed in that period. Histopathology slides and clinical records of all the cases were reviewed. Appropriate blocks were selected and sent
for immunohistochemistry marker study which included: DOG-1, CD117, S-100, desmin, smooth muscle actin (SMA), CD34 and vimentin.
(C) Results: Out of 15 cases of GIST, all presented as abdominal masses commonly located in small intestine of adult men with mean age being 56
years. All the GISTs showed positivity for CD117 and vimentin. Immunoreactivity for DOG-1 clone 1.1 was observed in 14 cases and DOG-1
clone k9 was positive in 2 out of 15 cases studied.
(D) Conclusion: This study validates the importance of CD117 in diagnosis of GIST. Out of two clones of DOG-1, clone 1.1 was observed to be
more sensitive marker.


Cd117, DOG-1, gastrointestinal stromal tumors, immunohistochemistry.

Full Text:



Fulop E, Marcu S, Milutin D, Borda A. Gastrointestinal stromal tumors: review on morphology, diagnosis and management. Rom J Morphol Embryol. 2009;50(3):319-26.

Streutker CJ, Huizinga JD, Driman DK, Riddell RH. Interstitial cells of cajal in health and disease. Part I: normal ICC structure and function with associated motility disorders. Histopathology. 2007 Jan;50(2):176-89.

Miettinen M, Wang ZF, Lasota J. DOG1 antibody in differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases. Am J Surg Pathol. 2009 sep;33(9):1401-8.

Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastrointestinal stromal tumors. Cancer Res Treat. 2010 sept;42(3):135-43.

Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003 Sep;125(3):660-7.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nashida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 jan;279(5350):577-80.

Foo WC, Liegl-Atzwanger B, Lazar AJ. Pathology of Gastrointestinal stromal tumors. Clin med insights Pathol. 2012;5:23-33.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. 2001 Jan;438(1):1-12.

Gonullu D, Demiray O, Ilgun S, Yildiz UM, Gedik ML, ER M, Igdem A, Kimiloglu E, Koksoy FN. Gastrointestinal stromal tumors: A clinical and histopathological presentation of 27 cases. Turk J Surg. 2018 Sep;34(4): 259-263.

Gonzalez-Campora R, Delgado MD, Amate AH, Gallardo SP, Leon MS, Beltran AL. Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors. Anal Quant Cytol Histol. 2011 Feb;33(1):1-11.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006 May;23(2):70-83.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Siberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med. 2001 Apr 5;344(14):1052-6.

Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch R, Halpren Z, Wassermann I, Halevy A. Gastrointestinal stromal tumors: a 19 year experience. Isr Med Assoc J. 2009 Feb;11(2):98-102.

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002 May;33(5):459-65.

Attili SV, Ananda B, Mandapal T, Anjaneyulu V, Sinha S, Reddy OC. Factors influencing progression-free survival in gastrointestinal stomal tumors with special reference to pathologic features, cytogenetics and radiologic response. Gastrointest Cancer Res. 2011 Sept;4(5-6):173-7.

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H et al. NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul;5 suppl 2:S1-29.

Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):205-20.

Patil DT, Rubin BP. Gastrointestinal stromal tumor: Advances in diagnosis and management. Arch Pathol Lab Med. 2011 Oct;135(10):1298-310.

Liu FY, Qi JP, Xu FL, Wu AP. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol. 2006 Jul 14;12(26):4161-5.


  • There are currently no refbacks.